HLVX 1.89 HilleVax, Inc.
| Range: | 1.55-20.22 | Vol Avg: | 424832 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | 0.8 | Cap: | 0.09B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Apr 29 2022 | Empoloyees: | 90 | ||
| CUSIP: | 43157M102 | CIK: | 0001888012 | ISIN: | US43157M1027 | Country: | US |
| CEO: | Dr. Robert M. Hershberg M.D., Ph.D. | Website: | https://www.hillevax.com | ||||
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Stock Details
Positive 0.17
What Makes HilleVax (HLVX) a New Buy Stock
HilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism ab...
zacks.com·Mon Oct 14 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow